Catalyst

Slingshot members are tracking this event:

Gilead (GILD) Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 24, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Bictegravir, Dolutegravir, Emtricitabine, Tenofovir Alafenamide, Hiv